Chromadex Corp
CDXC
Get informed when a big investor buys or sells
+ FollowMarket Cap$611.9M
Close$
$-0.10
101.3% downside
Current Fair Value
101.3% downsideOvervalued by 101.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $611.90 Million |
|---|---|
| Enterprise Value | $548.30 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 2.21 |
| Outstanding Shares | 79,917,000 |
Return
| Return on Equity | 22.64% |
|---|---|
| Return on Assets | 16.30% |
| Return on Invested Capital | 14.30% |
Valuation & Multiples
| P/E Ratio | 16.55 |
|---|---|
| PEG | 66.78 |
| Price to Sales | - |
| Price to Book Ratio | 7.87 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 41.91 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 4, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.5169▲ 23.00% |
|---|---|
| Total Calls | 94,800▼ 2.17% |
| Total Puts | 428,200▲ 3.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 46.44%▲ 5.68% |
|---|---|
| Total Invested | $162.31M▼ 20.76% |
| Investors Holding | 149▼ 25.00% |
ESG Score
No data
About Chromadex Corp
CEO: Robert Fried ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solut...